

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-019	HPAP-020	HPAP-021	HPAP-022	HPAP-023	HPAP-024	HPAP-026	HPAP-027
Donor age (years)	22	14	13	39	17	18	24	31
Donor sex (M/F)	M	M	F	F	F	M	M	F
Donor BMI (kg/m ²)	29.8	13.2	21.4	34.7	21.35	24.3	20.8	32.71
Donor HbA _{1c} or other measure of blood glucose control	5.2	NA	NA	4.7	8.9	5.5	4.9	4.4
Origin/source of islets ^b	nPod	nPod	nPod	UPenn	nPod	nPod	nPod	UPenn
Islet isolation centre	nPod	nPod	nPod	UPenn	nPod	nPod	nPod	UPenn
Donor history of diabetes? Please select yes/no from drop down list	No	Yes	Yes	No	Yes	No	No	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)		5 days	7		7			
Glucose-lowering therapy at time of death ^c		Insulin	Insulin (Tresiba, Novolog)		Insulin (Humalog, Levemir)			

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-028	HPAP-029	HPAP-032	HPAP-034	HPAP-035	HPAP-036	HPAP-037	HPAP-038
Donor age (years)	4	23	10	13	35	23	35	13
Donor sex (M/F)	M	M	F	M	M	F	F	M
Donor BMI (kg/m ²)	17.3	28.6	16.3	18.6	26.91	16	21.9	18.34
Donor HbA _{1c} or other measure of blood glucose control	9.8	5.3	9	5.2	5.2	5.2	5.3	5.7
Origin/source of islets ^b	nPod	nPod	nPod	UPenn	UPenn	nPod	UPenn	nPod
Islet isolation centre	nPod	nPod	nPod	UPenn	UPenn	nPod	UPenn	nPod
Donor history of diabetes? Please select yes/no from drop down list	Yes	No	Yes	No	No	No	No	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)	3		3					
Glucose-lowering therapy at time of death ^c	Insulin (Lantis, Apidra)		Insulin (Humalog)					

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-040	HPAP-042	HPAP-043	HPAP-044	HPAP-045	HPAP-047	HPAP-049	HPAP-050
Donor age (years)	35	1	15	3	27	8	29	21
Donor sex (M/F)	M	M	M	F	F	M	M	F
Donor BMI (kg/m ²)	23.98	17.9	24.07	12	26.2	16.82	37.2	28.99
Donor HbA _{1c} or other measure of blood glucose control	5.4	5.6	5.9	5.3	5.2	NA	5.4	5.1
Origin/source of islets ^b	UPenn	nPod	nPod	nPod	nPod	UPenn	nPod	nPod
Islet isolation centre	UPenn	nPod	nPod	nPod	nPod	UPenn	nPod	nPod
Donor history of diabetes? Please select yes/no from drop down list	No	No	No	No	No	No	No	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)								
Glucose-lowering therapy at time of death ^c								

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-051	HPAP-052	HPAP-053	HPAP-054	HPAP-055	HPAP-056	HPAP-057	HPAP-058
Donor age (years)	43	27	58	40	24	33	50	34
Donor sex (M/F)	F	M	F	F	M	M	F	F
Donor BMI (kg/m ²)	45.49	38.72	24.2	30.85	27.9	32.89	30.49	29.26
Donor HbA _{1c} or other measure of blood glucose control	6.7	5.2	5.6	4.8	10.4	5.6	5.8	9.4
Origin/source of islets ^b	UPenn	UPenn	UPenn	UPenn	UPenn	UPenn	UPenn	nPod
Islet isolation centre	UPenn	UPenn	UPenn	UPenn	UPenn	UPenn	UPenn	nPod
Donor history of diabetes? Please select yes/no from drop down list	Yes	No	No	No	Yes	No	Yes	Yes
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)	5-6				7		0.66666667	<1
Glucose-lowering therapy at time of death ^c	Metformin, Glimeperide, Glyxambi				Insulin		Metformin	

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-059	HPAP-061	HPAP-063	HPAP-064	HPAP-065	HPAP-070	HPAP-071	HPAP-072
Donor age (years)	35	59	45	24	40	55	12	19
Donor sex (M/F)	M	F	F	M	M	M	F	M
Donor BMI (kg/m ²)	37.96	38.27	38.41	16.98	37.47	17.09	15.42	23.1
Donor HbA _{1c} or other measure of blood glucose control	NA	5.9	6.3	NA	9.5	7	9.8	5.6
Origin/source of islets ^b	UPenn	UPenn	UPenn	UPenn	nPod	nPod	nPod	nPod
Islet isolation centre	UPenn	UPenn	UPenn	UPenn	nPod	nPod	nPod	nPod
Donor history of diabetes? Please select yes/no from drop down list	No	Yes	No	Yes	Yes	Yes	Yes	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)		Unknown		Unknown, diagnosed at admission	3	16	3	
Glucose-lowering therapy at time of death ^c		Metformin, Ozempic			Metformin	Metformin	Insulin glargine	

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-074	HPAP-075	HPAP-077	HPAP-079	HPAP-080	HPAP-081	HPAP-082	HPAP-083
Donor age (years)	40	35	47	52	22	45	25	45
Donor sex (M/F)	F	M	M	F	M	F	M	M
Donor BMI (kg/m ²)	36.88	27.52	32.78	28.38	35.71	28.91	23.96	35.62
Donor HbA _{1c} or other measure of blood glucose control	6.3	6	5.7	6.8	5.4	7.9	5.6	5
Origin/source of islets ^b	UPenn	UPenn	UPenn	nPod	nPod	nPod	nPod	UPenn
Islet isolation centre	UPenn	UPenn	UPenn	nPod	nPod	nPod	nPod	UPenn
Donor history of diabetes? Please select yes/no from drop down list	No	No	No	Yes	No	Yes	No	Yes
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)				10		20		2-3
Glucose-lowering therapy at time of death ^c				Metformin		Metformin, Lantus, Trulicity		Insulin

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-084	HPAP-085	HPAP-087	HPAP-088	HPAP-090	HPAP-091	HPAP-092	HPAP-093
Donor age (years)	12	48	15	37	59	50	21	50
Donor sex (M/F)	F	F	F	M	F	F	M	M
Donor BMI (kg/m ²)	18.5	39.78	19.3	32.81	32.23	35.58	25.59	34.98
Donor HbA _{1c} or other measure of blood glucose control	13.3	NA	10.4	10.3	8.7	NA	5.6	4.9
Origin/source of islets ^b	nPod	UPenn	nPod	nPod	nPod	nPod	nPod	UPenn
Islet isolation centre	nPod	UPenn	nPod	nPod	nPod	nPod	nPod	UPenn
Donor history of diabetes? Please select yes/no from drop down list	Yes	Yes	Yes	Yes	Yes	Yes	No	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)		6-10	6-10	<0.833	>3	0.25		
Glucose-lowering therapy at time of death ^c		Oral meds	Novolog	Unknown pills	Metformin, Glipizide			

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-099	HPAP-100	HPAP-101	HPAP-103	HPAP-104	HPAP-105	HPAP-106	HPAP-107
Donor age (years)	28	41	55	48	4	51	55	15
Donor sex (M/F)	F	M	F	F	M	F	M	M
Donor BMI (kg/m ²)	24.7	28.83	38.01	36.44	20.63	28.1	28.12	23.59
Donor HbA _{1c} or other measure of blood glucose control	5	10.7	5	6	4.9	5.2	5.8	5.3
Origin/source of islets ^b	UPenn	nPod	nPod	UPenn	UPenn	nPod	UPenn	nPod
Islet isolation centre	UPenn	nPod	nPod	UPenn	UPenn	nPod	UPenn	nPod
Donor history of diabetes? Please select yes/no from drop down list	No	Yes	No	No	No	No	Yes	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)		7-8					3	
Glucose-lowering therapy at time of death ^c							Metformin	

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	HPAP-108	HPAP-109						
Donor age (years)	42	59						
Donor sex (M/F)	M	F						
Donor BMI (kg/m ²)	33	29.49						
Donor HbA _{1c} or other measure of blood glucose control	10.8	7.5						
Origin/source of islets ^b	nPod	nPod						
Islet isolation centre	nPod	nPod						
Donor history of diabetes? Please select yes/no from drop down list	Yes	Yes						
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)		<5						
Glucose-lowering therapy at time of death ^c		Sitagliptin-metformin empagliflozin-metformin (Synjardy XR)						

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results